CARMAT, the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, announces interim information regarding its ongoing Feasibility clinical trial.

The third patient, who was implanted with a CARMAT prosthesis on April 8, 2015, died on the morning of December 18, 2015. Based on the information currently available, he died from acute respiratory failure while suffering from chronic kidney failure, after which the medical team stopped the prosthesis. This patient, aged 74, had returned home after being discharged at the end of August. He had been suffering from a combination of pre-existing pathologies when he was implanted with the prosthesis, including kidney failure, causing him to regularly return to the hospital. At this stage of the clinical trial, the CARMAT system has 20 months of combined clinical experience. As a reminder, the study’s criteria for success include the patient’s 30-day survival following implantation.

The analyses carried out do not show that the prosthesis was involved in the patient’s death. The Company is continuing the Feasibility study.